Keryx Biopharmaceuticals Announces Changes to its Board of Directors
September 13, 2017 16:10 ET
|
Keryx Biopharmaceuticals, Inc.
Mark Enyedy appointed to Keryx’s board of directorsCurrent Keryx board member Michael Rogers appointed chairman BOSTON, Sept. 13, 2017 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc....
Keryx Biopharmaceuticals to Webcast its Presentations at Investor Healthcare Conferences in September 2017
September 05, 2017 08:01 ET
|
Keryx Biopharmaceuticals, Inc.
BOSTON, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today...
Keryx Biopharmaceuticals to Webcast its Presentation at Canaccord Genuity’s 37th Annual Growth Conference on August 9, 2017
August 04, 2017 08:31 ET
|
Keryx Biopharmaceuticals, Inc.
BOSTON, Aug. 04, 2017 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today...
Keryx Biopharmaceuticals Announces Second Quarter 2017 Financial Results and Increased 2017 U.S. Product Sales Guidance
July 27, 2017 07:01 ET
|
Keryx Biopharmaceuticals, Inc.
Company reported $15.1 million in second quarter 2017 total revenues, including net U.S. Auryxia® (ferric citrate) product sales of $14.1 million, a 71 percent increase compared to the second quarter...
Keryx Biopharmaceuticals to Host Conference Call of Second Quarter 2017 Financial Results on Thursday, July 27, 2017
July 19, 2017 08:31 ET
|
Keryx Biopharmaceuticals, Inc.
BOSTON, July 19, 2017 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today...
Keryx Biopharmaceuticals to Webcast its Presentation at Jefferies’ 2017 Healthcare Conference on June 6, 2017
May 30, 2017 09:01 ET
|
Keryx Biopharmaceuticals, Inc.
BOSTON, May 30, 2017 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today...
Keryx Biopharmaceuticals Announces First Quarter 2017 Financial Results
May 04, 2017 07:02 ET
|
Keryx Biopharmaceuticals, Inc.
Company reported $11.8 million in first quarter 2017 total revenue, including net U.S. Auryxia® (ferric citrate) product sales of $10.5 million Provides 2017 net U.S. Auryxia product sales...
Keryx Announces that Auryxia® (Ferric Citrate) is Now on Formulary at All Major Medicare Part D Plans
May 01, 2017 07:40 ET
|
Keryx Biopharmaceuticals, Inc.
Company secures formulary status at another large Medicare Part D sponsor95 percent of dialysis patients on phosphate binders across Medicare Part D and commercial insurance providers now have...
Keryx Biopharmaceuticals to Host Conference Call of First Quarter 2017 Financial Results on Thursday, May 4, 2017
April 18, 2017 08:35 ET
|
Keryx Biopharmaceuticals, Inc.
BOSTON, April 18, 2017 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today...
Keryx Announces the Largest Medicare Part D Plan Sponsor Added Auryxia® to its Medicare Part D Plan Formularies
March 20, 2017 07:30 ET
|
Keryx Biopharmaceuticals, Inc.
BOSTON, March 20, 2017 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today...